SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent drug candidate to treat retinitis pigmentosa, the most common inherited retinal degeneration.

Biotechnology

SparingVision

Stéphane Boissel

Marie Uguen

Ryan Klimczak

Hélène Grimm

Mehdi Gasmi

Florence Paliargues

Anne-Sophie Gautron

Dan Chung

Rajiv Gangurde

Stanislas Piot

Florence Lorget

Clinical Advisory and Project Management

Finance and Corporate Development

Scientific Advisors

Leadership Team

Regulatory and Quality Assurance

��

Teams at SparingVision

Clinical Advisory and Project Management

Finance and Corporate Development

Scientific Advisors

Leadership Team

Regulatory and Quality Assurance

��������

Teams at SparingVision

Clinical Advisory and Project Management

Finance and Corporate Development

Scientific Advisors

Leadership Team

Regulatory and Quality Assurance

��